Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Covington
US Army
US Department of Justice
Accenture
Fish and Richardson
Merck
Daiichi Sankyo
Boehringer Ingelheim

Generated: June 23, 2018

DrugPatentWatch Database Preview

SURMONTIL Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Surmontil, and what generic alternatives are available?

Surmontil is a drug marketed by Odyssey Pharms and is included in one NDA.

The generic ingredient in SURMONTIL is trimipramine maleate. There are five drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the trimipramine maleate profile page.
Drug patent expirations by year for SURMONTIL
Pharmacology for SURMONTIL
Medical Subject Heading (MeSH) Categories for SURMONTIL
Synonyms for SURMONTIL
.beta.-Methylimipramine
( )-Trimipramine
(-)-Trimipramine
(+)-5-[3-(Dimethylamino)-2-methylpropyl]-10,11-dihydro-5H-dibenz[b,f]azepine
(+)-Trimipramine
(3-{2-azatricyclo[9.4.0.0;{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-yl}-2-methylpropyl)dimethylamine
(3-{2-azatricyclo[9.4.0.0?,?]pentadeca-1(11),3,5,7,12,14-hexaen-2-yl}-2-methylpropyl)dimethylamine
(3-{2-AZATRICYCLO[9.4.0.0(3),?]PENTADECA-1(11),3,5,7,12,14-HEXAEN-2-YL}-2-METHYLPROPYL)DIMETHYLAMINE
1-(3-Dimethylamino-2-methylpropyl)-4,5-dihydro-2,3:6,7-dibenzazepine
10,11 Dihydro-N,N,beta-trimethyl-5H-dibenz(b,f)azepine-5-propanamine
10,11-Dihydro-5-(3-dimethylamino-2-methylpropyl)-5H-dibenz(b,f)azepine
10,11-dihydro-N,N,beta-trimethyl-5H-dibenz[b,f]azepine-5-propanamine
10633 RP
10645 RP
10645RP
2'-Metil-3'-dimetilamino-propil-5-iminodibenzile
2'-Metil-3'-dimetilamino-propil-5-iminodibenzile [Italian]
20498-EP2275420A1
20498-EP2298764A1
20498-EP2298765A1
20498-EP2305260A1
20498-EP2305652A2
20498-EP2314585A1
25332-13-2 (mesylate)
3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N,2-trimethyl-1-propanamine
3-(10,11-Dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N,2-trimethyl-1-propanamine #
3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N,2-trimethylpropan-1-amine
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethyl-propan-1-amine
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethylpropan-1-amine
3564-66-7
3564-75-8
3589-21-7 (mono-hydrochloride)
3B1-007765
4CA-1282
5-(.gamma.-Dimethylamino-.beta.-methylpropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine
5-(3-(Dimethylamino)-2-methylpropyl)-10,11-dihydro-5H-dibenz(b,f)azepine
5-(gamma-Dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine
5-(gamma-dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo[b,f]azepine
5-[3-(dimethylamino)-2-methylpropyl]-10,11-dihydro-5H-dibenz[b,f]azepine
5-20-08-00099 (Beilstein Handbook Reference)
521-78-8 (maleate (1:1))
5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-
5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (-)- (9CI)
5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (-)-(9CI)
5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (+)-
5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (+)- (9CI)
5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (+)-(9CI)
5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(dimethylamino)-2-methylpropyl)-
5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(dimethylamino)-2-methylpropyl)-, (-)-
5H-Dibenz(b,f)azepine, 10,11-dihydro-5-(3-(dimethylamino)-2-methylpropyl)-, (+)-
5H-Dibenz(b,f)azepine, 5-(3-(dimethylamino)-2-methylpropyl)-
5H-Dibenz(b,f)azepine, 5-(3-(dimethylamino)-2-methylpropyl)-10,11-dihydro-
5H-Dibenz(b,f)azepine, 5-(3-(dimethylamino)-2-methylpropyl)-10,11-dihydro-, (-)-
5H-Dibenz(b,f)azepine, 5-(3-(dimethylamino)-2-methylpropyl)-10,11-dihydro-, (+)-
5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N,.beta.-trimethyl-
5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N,beta.-trimethyl-, (2Z)-2-butenedioate (1:1)
5H-Dibenz[b,f]azepine-5-propanamine,10,11-dihydro-N,N,b-trimethyl-
5H-Dibenz[b,f]azepine, 5-[3-(dimethylamino)-2-methylpropyl]-10,11-dihydro-
7162 RP
739-71-9
9K5931C1H5
AB00053646
AB00053646_10
AB00053646_11
AC-15969
AC1L1KO8
AKOS015962182
API0009047
BC209805
BDBM50240410
beta-Methylimipramine
BPBio1_000739
BRD-A19195498-050-05-9
BRN 1321466
BSPBio_000671
BSPBio_002701
cc-184
CCG-205230
CHEBI:9738
CHEMBL644
D00394
D00HZV
DB00726
DivK1c_000093
DTXSID8023715
EINECS 212-008-3
FI 6120
FT-0764503
GTPL7317
IDI1_000093
IL 6001
IL-6001
InChI=1/C20H26N2/c1-16(14-21(2)3)15-22-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)22/h4-11,16H,12-15H2,1-3H
J-525116
KBio1_000093
KBio2_001902
KBio2_004470
KBio2_007038
KBio3_002201
KBioGR_001118
KBioSS_001902
L000969
Lopac0_001156
LS-60463
LS-60464
LS-60465
NCGC00016013-02
NCGC00016013-03
NCGC00162356-01
NINDS_000093
Oprea1_375679
PL020516
Prestwick0_000806
Prestwick1_000806
Prestwick2_000806
Prestwick3_000806
QJ9MUH57H8
Rhotrimine (TN)
RL04798
RP-7162
Sapilent
SBI-0051123.P003
SCHEMBL35144
SPBio_001320
SPBio_002592
Spectrum_001422
Spectrum2_001530
Spectrum3_001151
Spectrum4_000759
Spectrum5_001052
Stangyl
Stangyl (TN)
STL483796
Surmontil (TN)
Surmontyl
Trimeprimina
Trimeprimina [Italian]
Trimeprimine
Trimeproprimin
Trimeproprimine
Trimipramina
Trimipramina [INN-Spanish]
trimipramine
Trimipramine (USAN/INN)
Trimipramine [USAN:INN:BAN]
Trimipramine 1.0 mg/ml in Methanol
Trimipramine Mesylate
Trimipramine Monohydrochloride
Trimipramine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material
Trimipramine, (-)-Isomer
Trimipraminum
Trimipraminum [INN-Latin]
UNII-9K5931C1H5
UNII-QJ9MUH57H8
ZSCDBOWYZJWBIY-UHFFFAOYSA-N

US Patents and Regulatory Information for SURMONTIL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Odyssey Pharms SURMONTIL trimipramine maleate CAPSULE;ORAL 016792-001 Approved Prior to Jan 1, 1982 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Odyssey Pharms SURMONTIL trimipramine maleate CAPSULE;ORAL 016792-002 Approved Prior to Jan 1, 1982 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Odyssey Pharms SURMONTIL trimipramine maleate CAPSULE;ORAL 016792-003 Sep 15, 1982 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Colorcon
Healthtrust
Cipla
AstraZeneca
Daiichi Sankyo
Express Scripts
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.